Venus Remedies Stock Screener | Share Price & Fundamental Analysis
VENUSREM
Pharmaceuticals
Screen Venus Remedies share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹691.15
▼
-28.20 (-3.92%)
Share Price BSE
₹740.10
▼
-10.85 (-1.44%)
Market Cap
₹991.16 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
1.71
EPS (TTM)
₹33.90
Dividend Yield
-
Debt to Equity
0.04
52W High
₹719.35
52W Low
₹428.15
Operating Margin
16.00%
Profit Margin
10.26%
Revenue (TTM)
₹195.00
EBITDA
₹33.00
Net Income
₹20.00
Total Assets
₹716.00
Total Equity
₹561.00
Venus Remedies Share Price History - Stock Screener Chart
Screen VENUSREM historical share price movements with interactive charts. Analyze price trends and patterns.
Venus Remedies Company Profile - Fundamental Screener
Screen Venus Remedies company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for VENUSREM shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE411B01019
Venus Remedies Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen VENUSREM balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 716 | 627 | 601 | 580 | 556 | 644 | 733 | 751 | 765 | 843 |
| Current Assets | 452 | 360 | 323 | 278 | 234 | 294 | 265 | 260 | 259 | 277 |
| Fixed Assets | 229 | 219 | 216 | 241 | 262 | 289 | 364 | 389 | 406 | 453 |
| Liabilities | ||||||||||
| Total Liabilities | 716 | 627 | 601 | 580 | 556 | 644 | 733 | 751 | 765 | 843 |
| Current Liabilities | 19 | 60 | 58 | 47 | 58 | 96 | 137 | 159 | 180 | 212 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 561 | 488 | 460 | 440 | 400 | 323 | 333 | 362 | 389 | 438 |
| Share Capital | 13 | 13 | 13 | 13 | 12 | 12 | 12 | 12 | 12 | 11 |
| Reserves & Surplus | 548 | 474 | 447 | 427 | 374 | 311 | 320 | 350 | 376 | 426 |
Screen VENUSREM income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 195 | 141 | 202 | 199 | 110 | 178 | 189 | 159 | 97 | 171 | 146 | 145 | 145 | 142 | 121 |
| Expenses | 162 | 122 | 166 | 176 | 97 | 163 | 159 | 131 | 85 | 150 | 131 | 137 | 129 | 127 | 109 |
| EBITDA | 33 | 19 | 36 | 23 | 13 | 16 | 30 | 28 | 13 | 21 | 14 | 8 | 16 | 15 | 12 |
| Operating Profit % | 16.00% | 11.00% | 15.00% | 10.00% | 10.00% | 4.00% | 10.00% | 16.00% | 11.00% | 11.00% | 8.00% | 4.00% | 10.00% | 9.00% | 7.00% |
| Depreciation | 6 | 6 | 5 | 6 | 6 | 6 | 5 | 8 | 8 | 6 | 7 | 8 | 8 | 9 | 7 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 27 | 13 | 31 | 18 | 7 | 9 | 25 | 20 | 5 | 14 | 8 | 0 | 8 | 6 | 5 |
| Tax | 6 | 3 | 10 | 7 | 6 | 6 | 5 | 9 | 4 | 4 | 1 | 0 | 1 | 0 | 1 |
| Net Profit | 20 | 10 | 21 | 11 | 1 | 4 | 20 | 11 | 1 | 10 | 7 | 0 | 7 | 5 | 3 |
| EPS | 15.06 | 7.18 | 15.71 | 7.86 | 0.92 | 2.63 | 14.66 | 8.27 | 0.88 | 7.44 | 5.13 | 0.17 | 5.16 | 3.99 | 2.46 |
Venus Remedies Cash Flow Screener - Liquidity Fundamentals
Screen VENUSREM cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 86 | 37 | 37 | 41 | 132 | 78 | 45 | 31 | 59 | 47 |
| Investing Activities | -77 | -9 | -58 | -17 | 57 | -5 | -11 | 9 | -18 | 3 |
| Financing Activities | -1 | -1 | -1 | -10 | -162 | -73 | -35 | -39 | -44 | -46 |
| Net Cash Flow | 9 | 28 | -22 | 14 | 27 | 0 | -1 | 0 | -4 | 4 |
Screen VENUSREM shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% |
| FII Holding | 1.34% | 2.24% | 1.86% | 1.48% | 1.06% | 1.18% | 1.11% | 0.00% |
| DII Holding | 0.00% | 0.11% | 0.75% | 0.15% | 0.15% | 0.15% | 0.00% | 0.15% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 46.81% | 47.70% | 45.30% | 46.89% | 46.25% | 45.31% | 45.42% | 49.24% |
| Other Holding | 10.09% | 8.19% | 10.33% | 9.73% | 10.78% | 11.61% | 11.71% | 8.85% |
| Shareholder Count | 19,982 | 19,307 | 17,725 | 19,913 | 19,614 | 19,557 | 19,771 | 21,719 |
Venus Remedies Dividend Screener - Share Yield Analysis
Screen VENUSREM dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
Venus Remedies Index Membership - Market Screener Classification
Screen VENUSREM by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Venus Remedies Market Events Screener - Corporate Actions
Screen VENUSREM market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | 0.93% | ||
| 2025-11-10 | 2025-11-10 | Quarterly Result Announcement | NA | 1.78% |
| 2025-08-22 | 2025-08-22 | Annual General Meeting | NA | 14.50% |
| 2025-08-01 | 2025-08-01 | Quarterly Result Announcement | NA | -2.92% |
| 2025-05-26 | 2025-05-26 | Quarterly Result Announcement | NA | 3.36% |
| 2025-02-04 | 2025-02-04 | Quarterly Result Announcement | NA | -1.96% |
| 2024-10-29 | 2024-10-29 | Quarterly Result Announcement | NA | -0.66% |
Venus Remedies Competitors Screener - Peer Comparison
Screen VENUSREM competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 412,734 | 39.30 | 54,729 | 9.71% | 10,980 | 39.06 |
| Divis Laboratories | 168,851 | 68.25 | 9,712 | 18.67% | 2,191 | 44.96 |
| Torrent Pharmaceuticals | 129,357 | 59.98 | 11,539 | 6.99% | 1,911 | 59.35 |
| Cipla | 120,557 | 22.21 | 28,410 | 7.12% | 5,291 | 42.76 |
| Dr Reddys Laboratories | 105,645 | 18.46 | 33,741 | 16.73% | 5,725 | 49.97 |
| Lupin | 95,023 | 21.85 | 22,910 | 13.74% | 3,306 | 50.10 |
| Zydus Life Science | 90,707 | 18.09 | 23,511 | 18.55% | 4,615 | 34.06 |
| Mankind Pharma | 88,846 | 50.78 | 12,744 | 20.90% | 2,007 | 40.67 |
| Aurobindo Pharma | 68,901 | 20.36 | 32,346 | 9.43% | 3,484 | 46.33 |
| Alkem Laboratories | 65,390 | 27.28 | 13,458 | 3.70% | 2,216 | 37.45 |
Venus Remedies Company Announcements - News Screener
Screen VENUSREM latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-03 | Copy Of Newspaper Notice Pertaining To Physical Transfer Of Shares. | View |
| 2025-12-31 | Closure of Trading Window | View |
| 2025-12-13 | Social Media Communication Regarding Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares Of Venus Remedies Limited. | View |
| 2025-12-12 | Shares Re-Lodged For Transfer Cum Demat Pursuant To SEBI Circular No. SEBI/HO/MIRSD/MIRSD-Pod/P/CIR/2025/97 Dated July 2 2025 For The Period July 7 2025 To November 30 2025 | View |
| 2025-12-08 | Venus Remedies Marks Completion Of AMR Licensing Milestones With Final ?11 Crore Payment | View |
| 2025-12-01 | Update On Resolution Of Income Tax Matters And Elimination Of Contingent Liability. | View |
| 2025-11-28 | Social Media Communication Regarding Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares Of Venus Remedies Limited | View |
| 2025-11-20 | Clarification On Movement In Volume | View |
| 2025-11-20 | Clarification sought from Venus Remedies Ltd | - |
| 2025-11-17 | Social Media Communication Regarding Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares Of Venus Remedies Limited | View |
| 2025-11-12 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-10 | Unaudited Financial Results As On 30Th September 2025 | View |
| 2025-11-10 | Board Meeting Outcome for Outcome Of Board Meeting Dated 10Th November 2025 | View |
| 2025-10-28 | Social Media Communication Regarding Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares. | View |
| 2025-10-27 | Board Meeting Intimation for Board Meeting Scheduled To Be Held On 10Th November 2025. | View |
| 2025-10-18 | SEBI Circular - Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares - Monthly Report. | View |
| 2025-10-10 | Social Media Communication Regarding Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares. | View |
| 2025-10-09 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-10-07 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-09-22 | Closure of Trading Window | View |